PERSISTENT BONE MARROW AND IMAGING MRD NEGATIVITY AS CRITERIA TO STOP LENALIDOMIDE MAINTENANCE FOLLOWING ASCT: PRELIMINARY RESULTS OF A SINGLE-CENTER PROSPECTIVE COHORT STUDY

EHA Library, Panagiotis Malandrakis, 386690

A PHASE 1 FIRST-IN-HUMAN MONOTHERAPY STUDY OF ABBV-383, A BCMA × CD3 BISPECIFIC T-CELL–REDIRECTING ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Katja Weisel, 386691

AN OPEN-LABEL PHASE I/IIA STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CCS1477 AS MONOTHERAPY AND IN COMBINATION WITH POMALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Emma Searle, 386692

TECLISTAMAB IN COMBINATION WITH LENALIDOMIDE IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA IN THE PHASE 1B MULTICOHORT MAJESTEC-2 STUDY

EHA Library, Carlyn Tan, 386694

IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA-3 SUBGROUP ANALYSIS BY PRIOR LINES OF THERAPY

EHA Library, Salomon Manier, 386695

CT103A, A NOVEL FULLY HUMAN BCMA-TARGETING CAR-T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS OF PHASE 1B/2 STUDY (FUMANBA-1)

EHA Library, Chunrui Li, 386696

MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE DOSE-EXPANSION PHASE OF THE CC-92480-MM-001 TRIAL

EHA Library, Nizar J Bahlis, 386697

UPDATED RESULTS OF A PHASE I, OPEN-LABEL STUDY OF BCMA/CD19 DUAL-TARGETING FASTCAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Juan Du, 386698

EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES

EHA Library, Salomon Manier, 386699

IDECABTAGENE VICLEUCEL (IDE-CEL) IN PATIENTS WITH AN INADEQUATE RESPONSE TO FRONTLINE AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): RESULTS FROM KARMMA-2 COHORT 2C

EHA Library, Melissa Alsina, 386700

EFFICACY OF DARATUMUMAB PLUS BORTEZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA PRESENTING WITH EXTRAMEDULLARY DISEASE: A EUROPEAN MYELOMA NETWORK STUDY (EMN19)

EHA Library, Meral Beksac, 386701

IXAZOMIB VERSUS LENALIDOMIDE OR IXAZOMIB AND LENALIDOMIDE COMBINATION AS MAINTENANCE REGIMEN FOR TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: UPDATE OF A MULTI-CENTER PROSPECTIVE STUDY IN CHINA

EHA Library, Junling Zhuang, 386702

REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY

EHA Library, Frida Bugge Askeland, 386704

ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE AND DARATUMUMAB OR BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA—FINAL EFFICACY AND SAFETY RESULTS

EHA Library, Enrique Maria Ocio San Miguel, 386705

IXAZOMIB DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY

EHA Library, Kaz Groen, 386706

SELINEXOR IN COMBINATION WITH DARATUMUMAB-BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF RELAPSE OR REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS OF THE PHASE 2, MULTICENTER GEM-SELIBORDARA STUDY

EHA Library, Paula Rodríguez-Otero, 386707

EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A SUBGROUP ANALYSIS FROM MAGNETISMM-3

EHA Library, Xavier Leleu, 386709

POMALIDOMIDE, DARATUMUMAB, AND DEXAMETHASONE AFTER LENALIDOMIDE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL OVERALL SURVIVAL ANALYSIS OF THE PHASE 2 MM-014 STUDY

EHA Library, Nizar J Bahlis, 386711

ALNUCTAMAB (ALNUC; BMS-986349; CC-93269), A BCMA × CD3 T-CELL ENGAGER, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LATEST RESULTS FROM A PHASE 1 FIRST-IN-HUMAN CLINICAL STUDY

EHA Library, Sandy W. Wong, 386712

BELANTAMAB MAFODOTIN PLUS LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: UPDATED RESULTS FROM THE PHASE 1/2 BELARD STUDY

EHA Library, Evangelos Terpos, 386713

SOLITARY PLASMACYTOMA: SINGLE INSTITUTION EXPERIENCE AND SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL OUTCOMES

EHA Library, Charalampos Charalampous, 386714

EFFICACY, SURVIVAL AND SAFETY OF SELINEXOR, BORTEZOMIB AND DEXAMETHASONE (SVD) IN PATIENTS WITH LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: SUBGROUP DATA FROM THE BOSTON TRIAL

EHA Library, María-Victoria Mateos, 386715

PROGNOSTIC VALUE OF POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY

EHA Library, Luis-Esteban Tamariz-Amador, 386716

MATCHED-ADJUSTED INDIRECT COMPARISON OF TALQUETAMAB VS SELINEXOR-DEXAMETHASONE AND VS BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Ajai Chari, 386717

POINT-OF-CARE ANTI-BCMA CAR T-CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH-RISK RELAPSE/REFRACTORY MULTIPLE MYELOMA

EHA Library, Hila Magen, 386718

COMBINING SKY92 GENE EXPRESSION PROFILING WITH CYTOGENETICS ACCORDING TO R2-ISS FOR MULTIPLE MYELOMA RISK CLASSIFICATION: THE FIRST PROSPECTIVE EVIDENCE

EHA Library, Xiang Zhou, 386719

IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RRMM PATIENTS: RESULTS OF THE MULTICENTER PHASE 2 STUDY (IFM 2018-02) OF THE INTERGROUPE FRANCOPHONE DU MYÉLOME (IFM).

EHA Library, Margaret Macro, 386720

COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS PHYSICIAN’S CHOICE THERAPY IN TRIPLE-CLASS EXPOSED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHED COHORT ANALYSIS

EHA Library, Albert Oriol, 386722

INFECTION RISK BEFORE DIAGNOSIS OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE: RESULTS FROM THE SCREENED POPULATION-BASED ISTOPMM STUDY

EHA Library, Marina Ros Levy, 386723

DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION: UPDATED ANALYSIS OF THE DEDALO PHASE II TRIAL

EHA Library, Vittorio Montefusco, 386724

VALUE OF 18F-FDG PET/CT IN THE EVALUATION OF ORGAN INVOLVEMENT IN NEWLY DIAGNOSED PRIMARY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS

EHA Library, Junru Liu, 386725

EVALUATION OF THE PROGNOSTIC IMPACT OF SECOND LINE ANTI-MYELOMA TREATMENTS ON POST- PROGRESSION OUTCOMES IN THE REAL-WORLD SETTING: THE GREEK MYELOMA STUDY GROUP EXPERIENCE.

EHA Library, Eirini Katodritou, 386726

A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS

EHA Library, Raija Silvennoinen, 386727

HOVON 104; LONG TERM FOLLOW-UP OF AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER BORTEZOMIB INDUCTION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS

EHA Library, Monique Minnema, 386728

INVOLVED/UNINVOLVED SERUM FREE LIGHT CHAIN RATIO IS A STRONGER PREDICTOR OF DIAGNOSTIC/RISK FACTORS IN LIGHT CHAIN COMPARED TO HEAVY CHAIN MONOCLONAL GAMMOPATHIES

EHA Library, Jon Thorir Oskarsson, 386729

DARATUMUMAB, IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PRE-TREATED WITH A LENALIDOMIDE-BASED REGIMEN: FINAL OUTCOMES OF THE PHASE 2 DARIA STUDY

EHA Library, Evangelos Terpos, 386730

ISATUXIMAB, WEEKLY CARFILZOMIB AND DEXAMETHASONE AS SALVAGE THERAPY FOR RRMM; INTERIM RESULTS FROM A PHASE 2 TRIAL.

EHA Library, David H. Vesole, 386731

CLINICAL UTILITY OF MONOCLONAL GAMMOPATHY SCREENING IN THE EVALUATION OF PERIPHERAL NEUROPATHY

EHA Library, Mackenzie Maberry, 386732

LOCOMMOTION: A PROSPECTIVE, OBSERVATIONAL, MULTINATIONAL STUDY OF REAL-LIFE CURRENT STANDARDS OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA– FINAL ANALYSIS AT 2-YEAR FOLLOW-UP

EHA Library, Philippe Moreau, 386733

GENOMIC ANALYSIS TO IDENTIFY DETERMINANTS OF INHERENT RESPONSE AND RESISTANCE TO ELRANATAMAB IN MAGNETISMM-3 COHORT A

EHA Library, Paula Rodríguez-Otero, 386735

EFFICACY AND SAFETY OF ELRANATAMAB IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3

EHA Library, Cyrille Touzeau, 386736

IDENTIFICATION OF CYTOKINES ASSOCIATED WITH RESPONSE AND CYTOKINE RELEASE SYNDROME – ANALYSIS OF MAGNETISMM-3 COHORT A

EHA Library, Katja Weisel, 386737

POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE CHEMOTHERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: POMACE PHASE II STUDY

EHA Library, Fen Saj, 386738

DISPARATE PREDICTION OF OUTCOMES IN A UNIFORMLY TREATED COHORT OF PATIENTS WITH AL AMYLOIDOSIS STRATIFIED BY MAYO 2012 AND EUROPEAN CARDIAC STAGING SYSTEMS

EHA Library, Jahanzaib Khwaja, 386739

ADDING REFRACTORINESS STATUS TO LINES OF THERAPY BETTER DEFINE PROGNOSIS OF A REAL LIFE ITALIAN MULTIPLE MYELOMA POPULATION

EHA Library, Sonia More', 386741

LOW-DOSE BELANTAMAB MAFODOTIN (BELAMAF) IN COMBINATION WITH NIROGACESTAT VS BELAMAF MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1/2 DREAMM-5 PLATFORM SUB-STUDY 3

EHA Library, Sebastian Grosicki, 386742

VENETOCLAX IN RELAPSE/REFRACTORY AL AMYLOIDOSIS- A MULTICENTER INTERNATIONAL RETROSPECTIVE REAL-WORLD STUDY

EHA Library, Iuliana Vaxman, 386743

TREATMENT PATTERNS AND CLINICAL OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY TREATED WITH LENALIDOMIDE AND AN ANTI-CD38 MONOCLONAL ANTIBODY: FINDINGS FROM THE CONNECT MM DISEASE REGISTRY

EHA Library, Rafat Abonour, 386744

SELINEXOR, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: UPDATED RESULTS OF BOSTON TRIAL BY PRIOR THERAPIES

EHA Library, María-Victoria Mateos, 386746

ROLE OF THE COMBINATION OF FDG PET PLUS WHOLE BODY MRI FOR STAGING PATIENTS IN HIGH RISK SMOLDERING MYELOMA: A PROSPECTIVE TRIAL

EHA Library, Claudio Cerchione, 386747

TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WITH ZOLEDRONIC ACID FOR FOUR YEARS INSTEAD OF TWO YEARS DECREASES RISK OF PROGRESSIVE BONE DISEASE WITHOUT INCREASING RISK OF OSTEONECROSIS OF THE JAW.

EHA Library, Thomas Lund, 386748

EVALUATION OF EARLY PROGRESSIVE DISEASE (EPD) IN NEWLY DIAGNOSED MYELOMA PATIENTS AND IDENTIFICATION OF PROGNOSTIC FACTORS IN THE ERA OF MODERN THERAPIES. THE GREEK MYELOMA STUDY GROUP EXPERIENCE.

EHA Library, Eirini Katodritou, 386749

ARTIFICIAL INTELLIGENCE BASED FDG PET/CT RADIOMICS FOR RISK STRATIFICATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Jacob Shreve, 386750

ADJUSTED COMPARISONS OF CILTACABTAGENE AUTOLEUCEL WITH THERAPIES FROM REAL-WORLD CLINICAL PRACTICE: TWO-YEAR FOLLOW-UP ANALYSES FROM CARTITUDE-1 AND THE PROSPECTIVE LOCOMMOTION STUDY

EHA Library, María-Victoria Mateos, 386751

COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF TREATMENT IN LOCOMMOTION AND MOMMENT FOR PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Hermann Einsele, 386752

TREATMENT PATTERNS OF TRIPLE-CLASS REFRACTORY (TCR) MULTIPLE MYELOMA (MM) ACROSS THE UNITED STATES (US), CANADA, AND WESTERN EUROPE: A REAL-WORLD OBSERVATIONAL CHART REVIEW STUDY

EHA Library, Ravi K Goyal, 386753

PHASE 1 TRIAL OF ANTI-CD38 MONOCLONAL ANTIBODY CM313 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA OR LYMPHOMA

EHA Library, Wenming Chen, 386754

ELEVATED SERUM LEVELS OF SOLUBLE B-CELL MATURATION ANTIGEN AS A PROGNOSTIC BIOMARKER FOR MULTIPLE MYELOMA

EHA Library, Juan Du, 386755

ACTUAL USAGE OF CURRENT SYSTEMIC TREATMENTS AND INFLUENCE OF KEY DRIVERS FOR MULTIPLE MYELOMA IN THE FIRST 2 LINES OF THERAPY. DATA FROM REAL-WORLD STUDY IN EU5 COUNTRIES.

EHA Library, Nicolas Blin, 386756

OCULAR ADVERSE EVENTS AND FUNCTIONAL IMPACT IN TRANSPLANT INELIGIBLE, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL

EHA Library, Evangelos Terpos, 386757

CIRCULATING TUMOR DNA ASSESSMENT IMPROVES PROGNOSTIC PREDICTION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING IXAZOMIB, LENALIDOMIDE, AND DEXAMETHASONE

EHA Library, Yasunori Kogure, 386758

ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNETISMM-5 STUDY, PART 2

EHA Library, Xavier Leleu, 386759

ISATUXIMAB IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH ULTRA-HIGH-RISK CYTOGENETICS: ICARIA-MM AND IKEMA SUBGROUP ANALYSIS

EHA Library, Philippe Moreau, 386760

INDIRECT TREATMENT COMPARISON OF ELRANATAMAB WITH BELMAF, SEL-DEX, AND REAL-WORLD PHYSICIAN’S CHOICE OF TREATMENT IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA.

EHA Library, Patrick Hlavacek, 386762

THE EFFECTS OF EXTRAMEDULLARY DISEASE ON OUTCOMES OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Yi Tao, 386763

EARLY RELAPSE WITHIN 18 MONTHS (ER18) IS A POWERFUL DYNAMIC PREDICTOR FOR PROGNOSIS AND COULD REVISE STATIC RISK DISTRIBUTION IN PATIENTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA

EHA Library, Wenqiang Yan, 386764

EXPLORING HETEROGENEITY IN TREATMENT PREFERENCES OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN THE UNITED STATES, UNITED KINGDOM, FRANCE, SPAIN, ITALY AND GERMANY

EHA Library, Rakesh Popat, 386765

CARFILZOMIB, LENALIDOMIDE PLUS DEXAMETHASONE (KRD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: UPDATE ANALYSIS OF REAL-LIFE EXPERIENCE OF GEMMAC GROUP.

EHA Library, Antonio Garcia-Guiñon, 386766

SURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA IN THE GENERAL POPULATION BASED ON DATA FROM TWO FRENCH CANCER REGISTRIES

EHA Library, Hakima Mechiche, 386767

THE RELATIONSHIP OF BONE MARROW FIBROSIS WITH EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA

EHA Library, Hilal Konyaoglu, 386768

AN OUTPATIENT MODEL FOR TECLISTAMAB STEP-UP DOSING ADMINISTRATION – INITIAL EXPERIENCES AT FOX CHASE CANCER CENTER BMT PROGRAM.

EHA Library, Asya Nina Varshavsky-Yanovsky, 386769

SERUM CXCL13 LEVEL AIDS IN DISEASE REMISSION EVALUATION AND PROGNOSIS PREDICTION IN WALDENSTRÖM MACROGLOBULINEMIA

EHA Library, JIA CHEN, 386770

MULTIPLE MYELOMA OLIGOSECRETORY RELAPSE- A CROSS SECTIONAL HISTORICAL COHORT STUDY

EHA Library, Yael Cohen, 386771

OUTCOME ANALYSIS BY CYTOGENETIC RISK GROUP AFTER RANDOMIZATION TO KRD OR KTD FOLLOWED BY K MAINTENANCE OR CONTROL IN PATIENTS WITH NTE NDMM (AGMT MM-02)

EHA Library, Heinz Ludwig, 386772

REAL-WORLD PATIENT CHARACTERISTICS AND SURVIVAL OUTCOMES OF LENALIDOMIDE REFRACTORY VS. LENALIDOMIDE EXPOSED RRMM PATIENTS IN THE HONEUR FEDERATED DATA NETWORK

EHA Library, Ivan Spicka, 386773

REAL-WORLD CLINICAL OUTCOMES AMONG TRIPLE-CLASS EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS IN US AND EUROPE: A PREAMBLE REGISTRY STUDY

EHA Library, Hartmut Goldschmidt, 386774

TOCILIZUMAB PRE-TREATMENT SIGNIFICANTLY REDUCES THE INCIDENCE OF CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE CEVOSTAMAB

EHA Library, María-Victoria Mateos, 386775

TREATMENT PATTERNS AND OUTCOMES OF RE-INDUCTION THERAPIES PRIOR TO STEM CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED IN CLINICAL PRACTICE IN GERMANY

EHA Library, Sandra Sauer, 386776

REAL-WORLD EVIDENCE OF BISPHOSPHONATES FOR MULTIPLE MYELOMA

EHA Library, Maria Nieves Lopez Muñoz, 386777

COMBINATION GA AND MPR VULNERABILITY SCORING TOOLS EFFECTIVELY IMPROVE THE ABILITY TO IDENTIFY THE FRAIL ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Li Bao, 386778

PRIOR CANCER AND RISK OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS): A POPULATION-BASED STUDY IN ICELAND AND SWEDEN

EHA Library, Sæmundur Rögnvaldsson, 386779

IMPACT OF MEASURABLE RESIDUAL DISEASE (MRD) DIFFERENCES ON PROGRESSION-FREE SURVIVAL (PFS): AN AGGREGATE DATA ANALYSIS FROM RANDOMIZED CLINICAL TRIALS IN MULTIPLE MYELOMA (MM)

EHA Library, Bruno Paiva, 386780

PROGNOSTIC SIGNIFICANCE OF DYNAMIC CHANGE OF MAGE-C1/CT7 IN MULTIPLE MYELOMA: TEN YEAR EXPERIENCE FROM A SINGLE CENTER

EHA Library, Xuelin Dou, 386781

ROLE OF THE COMBINATION OF FDG PET PLUS WHOLE BODY MRI FOR STAGING NEWLY DIAGNOSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE TRIAL

EHA Library, Claudio Cerchione, 386782

MULTIPLE MYELOMA IN LATIN AMERICA CANCER REGISTRY: THE MYLACRE STUDY

EHA Library, Vania Hungria, 386783

BURDEN OF INFECTION IN PATIENTS WITH MULTIPLE MYELOMA AND SECONDARY IMMUNODEFICIENCIES: A RETROSPECTIVE COHORT STUDY

EHA Library, Joshua Richter, 386784

VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM (R2-ISS) FOR OVERALL SURVIVAL IN MULTIPLE MYELOMA IN  A REAL WORLD COHORT:  AN ANALYSIS BY THE BALKAN MYELOMA STUDY GROUP (BMSG)

EHA Library, Efstathios Kastritis, 386785

AN INDIRECT COMPARISON OF ELRANATAMAB’S (ELRA) OBJECTIVE RESPONSE RATE (ORR) FROM MAGNETISMM-3 (MM-3) VERSUS REAL-WORLD EXTERNAL CONTROL ARMS IN TRIPLE-CLASS REFRACTORY (TCR) MULTIPLE MYELOMA (MM)

EHA Library, Luciano J. Costa, 386786

REAL-WORLD TREATMENT PATTERNS IN PATIENTS INITIATING THIRD-LINE THERAPY FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN GERMANY, ITALY, THE UK, FRANCE, AND SPAIN

EHA Library, Karthik Ramasamy, 386787

MAINTENANCE THERAPY FOLLOWED AUTOLOGOUS STEM CELL TRANSPLANTATION BY IXAZOMIB AND/OR LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A MULTICENTERED REAL WORLD STUDY IN CHINA

EHA Library, Li Bao, 386788

EXTRAMEDULLARY MYELOMA REMAINS AN UNMET CLINICAL NEED EVEN IN THE ERA OF NOVEL AGENT. ANALYSIS OF THE SINGLE CENTER MCOHORT.

EHA Library, Annamaria Brioli, 386789

MARIBAVIR (MBV) VERSUS INVESTIGATOR-ASSIGNED THERAPY FOR REFRACTORY CYTOMEGALOVIRUS (CMV) INFECTION: SUBGROUPS ANALYSES OF PHASE 3 STUDY BY RESISTANCE STATUS KNOWLEDGE REPORTED BY INVESTIGATORS.

EHA Library, Rafael F Duarte, 387994

TACROLIMUS MODULATES CD4+ T-CELL PROLIFERATION AND FUNCTION VIA MTHFD2 IN IMMUNE THROMBOCYTOPENIA

EHA Library, Li-Ping Yang, 387995

IL-1Β SIGNALLING INDUCES, AND BARICITINIB ALLEVIATES NEU1-MEDIATED MEGAKARYOCYTE DESIALYLATION IN IMMUNE THROMBOCYTOPENIA

EHA Library, Peng Zhao, 387996

CANCER RISK IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA – A DANISH NATIONWIDE COHORT STUDY

EHA Library, Nikolaj Mannering, 387997

MATERNAL AND FETAL OUTCOMES IN PREGNANCIES OF WOMEN WITH IMMUNE THROMBOCYTOPENIA: A MULTICENTER RETROSPECTIVE OBSERVATIONAL ITP-NET  ITALIAN STUDY

EHA Library, Monica Carpenedo, 387998

ORELABRUTINIB, AN IRREVERSIBLE INHIBITOR OF BRUTON’S TYROSINE KINASE, FOR TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA: RESULTS OF A RANDOMIZED, OPEN-LABEL PHASE II STUDY

EHA Library, Ming Hou, 387999

ASSESSMENT OF JOINT HEALTH IN PATIENTS RECEIVING PROPHYLAXIS FOR HAEMOPHILIA A IN FIVE EUROPEAN COUNTRIES: A CROSS-SECTIONAL SURVEY

EHA Library, Hortensia de la Corte Rodriguez, 388000

CONSUMPTION OF FACTOR CONCENTRATES AND BYPASSING AGENTS FOR MANAGEMENT OF BREAKTHROUGH BLEEDS WITH FITUSIRAN PROPHYLAXIS IN PEOPLE WITH HAEMOPHILIA A OR B: ANALYSIS OF ATLAS-PPX

EHA Library, Beatrice Nolan, 388001

LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF THE ADVANCE+ STUDY

EHA Library, Monica Carpenedo, 388002